Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).


Creative Commons License

Levy B., Barlesi F., Paz-Ares L., Bennouna J., Erman M., Felip E., ...More

Lung cancer (Amsterdam, Netherlands), vol.166, pp.107-113, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 166
  • Publication Date: 2022
  • Doi Number: 10.1016/j.lungcan.2022.01.023
  • Journal Name: Lung cancer (Amsterdam, Netherlands)
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, EMBASE, MEDLINE
  • Page Numbers: pp.107-113
  • Keywords: Carcinoma, Squamous Cell, Afatinib, Pembrolizumab, OPEN-LABEL, DOCETAXEL, TRIALS
  • Open Archive Collection: AVESIS Open Access Collection
  • Istanbul University-Cerrahpasa Affiliated: No

Abstract

Introduction: Afatinib and pembrolizumab have separately shown survival benefit in patients with squamous cell carcinoma (SqCC) of the lung, and there is biological rationale for concurrent inhibition of the programmed death ligand-1 and epidermal growth factor receptor (EGFR) pathways in this patient population.